Skip to content

The effect of minocycline on the post myocardial infarction left ventricular function in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention

The effect of minocycline on the post myocardial infarction left ventricular function in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201411188698N15
Enrollment
90
Registered
2015-06-22
Start date
2014-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. myocardial infarction specified as acute or with a stated duration of 4 weeks (28 days) or less from onset

Interventions

Intervention 1: Minocycline 50 mg orally at baseline and then 50 mg daily for 5 days. Intervention 2: Placebo in the form of the main drug orally at baseline and then daily for 5 days.
Treatment - Drugs
Placebo
Minocycline 50 mg orally at baseline and then 50 mg daily for 5 days
Placebo in the form of the main drug orally at baseline and then daily for 5 days

Sponsors

Tehran Heart Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: 1- Diagnosis of STEMI (chest pain>30 minutes and 1 mm in at least 2 consecutive leads) 2- No history of heart failure 3- Giving consent to enter the study 4- Age>20 and <65 years 5- Successful PCI exclusion criteria: 1- History of myocardial infarction 2- History of cardiac surgery (either CABG or valvular surgery) 3- History of electrophysiological interventions (ablation or device implantation) 4- Presence of cardiogenic shock at the time of admission 5- Chronic diseases with poor survival (malignancy, etc.) 6- Cardiomyopathy or hereditary muscular diseases 7- Chronic renal or hepatic insufficiency 8- new onset left bundle branch block in ECG 9- candidate for antithrombolytic therapy 10- Moderate to severe mitral regurgitation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Left ventricular function. Timepoint: Baseline (within 48 hours from PCI) and 6 months later. Method of measurement: Echocardiography.

Secondary

MeasureTime frame
Diastolic function. Timepoint: Baseline (within 48 hours from PCI) and 6 months later. Method of measurement: Echocardiography.;Tissue doppler indices. Timepoint: Baseline (within 48 hours from PCI) and 6 months later. Method of measurement: Color Doppler Echocardiography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Nasiri

Tehran Heart Center

Alirezanasiri6584@yahoo.com+98 21 8802 9600

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 19, 2026